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The Emerging Risk Factors Collabora-tion (1) has recently confirmed thattype 2 diabetes remains associated
with substantial premature mortality.
Compared with nondiabetic individuals,
those with diabetes have a hazard ratio
(HR) of 1.80 (95% CI 1.71–1.90) for
death from any cause, 1.25 (1.19–1.31)
for death from cancer, 2.32 (2.11–2.56)
for death from vascular causes, and 1.73
(1.62–1.85) for death from other causes.
As is apparent, the greater risk is owing to
cardiovascular (CV) disease, which ac-
counts for .60% of the years of life lost
because of diabetes. Although this in-
crease in CV risk is largely attributable
to the coexistence of multiple metabolic
and hemodynamic disorders, elevation of
plasma glucose levels remains strongly as-
sociated with increased CVmorbidity and
mortality (2–4). In support of a potential
direct effect of plasma glucose elevation is
the association between fasting plasma
glucose levels .100 mg/dL (5.6 mmol/L)
and vascular death (1). Since this a near-
linear association (1,5) it has been postu-
lated that reduction of plasma glucose
levels should exert a positive impact on
CV morbidity and mortality.
In the UK Prospective Diabetes Study
(UKPDS), improvement of glycemic con-
trol was associated with a 16% reduction
in the risk of myocardial infarction with-
out achieving statistical significance (P ,
0.052) (6). Glycemic control in that
seminal trial was, however, relatively
unsuccessful. Though intensively treated
patients achieved an average A1C of 7%, a
progressive worsening in glycemic con-
trol occurred after the initial improve-
ment. A more aggressive and successful
approach was adopted in the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) (7) and Action in Diabetes
and Vascular Disease: Preterax and Dia-
micron MR Controlled Evaluation
(ADVANCE) (8) trials and Veterans
Affairs Diabetes Trial (VADT) (9). In all
these three large studies, glycemic control
was achieved (A1C 6.5–7.0%) and main-
tained over a substantial period of time
(3.4–6.0 years). Nonetheless, no signifi-
cant impact on CV outcome was ob-
served. Only when all intervention trials
were included in a meta-analysis did a 9%
(HR 0.91 [95% CI 0.84–0.99]) reduction
in major CV events become apparent, pri-
marily because of a 15% risk reduction of
myocardial infarction (0.85 [0.76–0.94])
with no effect on CV mortality (10).
Several hypotheses have been pro-
posed in the attempt to account for the
lack of an effect of good glycemic control
on CV risk (11,12). Among these, it was
claimed that the diabetic population in-
cluded in these trials was not the most
appropriate one because of long-standing
duration of diabetes with a large percent-
age of the patients who already had
micro- and macrovascular complications
(11). Others questioned the use of some
antihyperglycemic medicines used to
assure good glycemic control (12). In
support of these claims are the post-
UKPDS results showing that in type 2
diabetic patients who were intensively
treated since diagnosis, a significant re-
duction of both micro- and macrovascu-
lar complications was apparent 10 years
after termination of the active study (13).
On the other hand, attention was drawn
to the potential atherogenic effect of large
doses of insulin often used in these inter-
vention trials.
These considerations have raised two
main questions: 1) Could diabetic patients
with shorter diabetes duration or even
with prediabetes benefit more from near-
normal plasma glucose level normaliza-
tion? 2) Could this be achieved with early
use of insulin? To some extent, the Out-
come Reduction With Initial Glargine In-
tervention (ORIGIN) trial (14) was design
to address these questions.
ORIGIN trial
The main question addressed by the
ORIGIN trial (14) was whether insulin re-
placement therapy targeting fasting nor-
moglycemia (#95 mg/dL or 5.3 mmol/L)
with insulin glargine in subjects in a rela-
tively early stage of the disease and mod-
erate hyperglycemia as well as in subjects
with impaired glucose regulation could
reduce CV outcomes more than standard
treatment. A total of 12,537 high–CV dis-
ease risk patients, including 1,456 indi-
viduals with prediabetes (impaired
fasting glucose [IFG] or impaired glucose
tolerance [IGT]) were randomized to
standard care (mainly oral hypoglycemic
agents) or to insulin glargine. Over a me-
dian 6.2 years of follow-up, a modest gly-
cemic separation between groups was
obtained with a 0.3% A1C difference by
the end of the study, with both groups
achieving A1C #6.5%. Inclusion in the
trial of high–CV disease risk subjects re-
sulted in an event rate (first coprimary
outcome: composite of CV death, myo-
cardial infarction, stroke, and CV death)
of;3% per year with no difference in the
two treatment groups (2.94 vs. 2.85/100
person-years; HR 1.02 [95% CI 0.94–
1.11]; P = 0.63). Similarly, no difference
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was apparent with respect to second
coprimary end points (composite of re-
vascularization procedures or hospitaliza-
tion for heart failure, 5.52 vs. 5.28/100
person-years; HR 1.04 [0.97–1.11];
P = 0.27). Insulin glargine treatment was
associated with a rate of severe hypogly-
cemia of 1.00/100 person-years com-
pared with 0.31/100 person-years with
standard care. Moreover, in the insulin
glargine group, body weight increased
by 1.6 kg compared with 20.5 kg de-
crease in patients randomized to standard
care. Finally, 3 months after therapy was
stopped, new diabetes, as diagnosed by
oral glucose tolerance test [OGTT], was
found in 30 vs. 35% of the subjects with
prediabetes at baseline (odds ratio [OR]
0.80 [95% CI 0.64–1.00]; P = 0.05). Can-
cer events were also monitored and adju-
dicated throughout the study. There was
no association between use of insulin
glargine and risk of any form of cancer
(HR 1.00 [95% CI 0.88–1.13]; P = 0.97)
The results of this study are far from
being clear-cut, as they can be read in
different ways. Overall, the impression is
that we have, once again, a classic half-
full, half-empty glass. Therefore, some
consideration is worthy with respect to
the rationale of the study, the population
that has been included, and the implica-
tions of the treatments adopted.
Study rationale
In the meta-analysis of 20 studies per-
formed by Coutinho et al. (5) including
95.783 subjects with a median follow-up
of 12.4 years and a total of 3.707 CV
events, a positive association was found
between fasting plasma glucose and CV
events. As confirmed in recent analysis
(1), this association was also present for
nondiabetic fasting hyperglycemia. Com-
pared with a reference fasting plasma glu-
cose of 75 mg/dL (4.2 mmol/L), a plasma
glucose level of 100 mg/dL (5.6 mmol/L)
was associated with a 33% increase of CV
risk (5). Therefore, fasting plasma glucose
can be seen as a sound therapeutic target,
as it has been in the ORIGIN trial (15).
The authors, however, must be very well
aware of epidemiologic data suggesting
that post-OGTT and, therefore, postpran-
dial glucose may be a better predictor of
CV morbidity and mortality. In the meta-
analysis by Coutinho et al. (5), CV risk
increased to 58% for a 2-h OGTT of 140
mg/dL (7.8 mmol/L). This finding is cor-
roborated by the results of the Diabetes
Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Europe (DECODE)
study (16) including data from 13 Euro-
pean prospective surveys. The study
showed a 20% increase in risk of all-cause
mortality in IFG individuals compared
with 50% increase in those with IGT. An
association between all-cause mortality
and fasting plasma glucose was apparent
only for 2-h plasma glucose#140 mg/dL
(7.8 mmol/L), whereas the latter re-
mained an independent predictor even af-
ter adjustment for fasting plasma glucose.
When CV disease was considered (17),
fasting plasma glucose had less predictive
power (HR 1.20 [95% CI 0.88–1.64] for
mortality from CV disease and 1.09
[0.71–1.67] from coronary heart disease)
compared with 2-h plasma glucose (1.40
[1.02–1.92 ] and 1.56 [1.03–2.36], re-
spectively) (Fig. 1).
Therefore, tackling fasting rather than
postprandial glucose may have reduced
the possibility of affecting CV outcomes.
Though increased basal plasma glucose
levels may sustain vessel damage (18,19),
a large literature body supports a more del-
eterious effect of postprandial hyperglyce-
mia (20–22).
In line with this possibility are the
results of the Study to Prevent Non–
Insulin-Dependent Diabetes Mellitus
(STOP-NIDDM) trial showing that acar-
bose, possibly through diminution of ox-
idative stress induced by postprandial
glycemic excursion, was associated
with a 49% risk reduction of CV events
(23). In a subgroup of subjects, acarbose
treatment was accompanied by a 50% de-
crease in the progression of intima-media
thickness of carotid arteries (24).
Finally, a meta-analysis of seven major
studies showed that the use of acarbose
in type 2 diabetes was associated with a
35% risk reduction of CV disease (25).
The other study carried out in prediabetic
patients for which postprandial glucose
ideally was the main treatment target is
the Nateglinide And Valsartan in Im-
paired Glucose Tolerance Outcomes Re-
search (NAVIGATOR) trial (26). The
study was largely negative, as the use of
nateglinide in prediabetic individuals was
not associated with significant reduction
in the development of type 2 diabetes and
CV events. However, in the NAVIGATOR
trial, mean 2-hOGTT glucose levels in the
annual tests were higher in the nateglinide
group than in the placebo group. Finally,
A1C data were not presented, other than
in the subgroup that progressed to diabe-
tes, to assess whether a significant overall
improvement in glycemic control was
obtained.
In summary, whether fasting or post-
prandial plasma glucose may be a better
target in the attempt to reduce CV events
in subjects with diabetes or at risk for
diabetes remains to be determined. How-
ever, while there was no significant re-
duction in CV with insulin glargine in the
ORIGIN trial, the use of acarbose was
associated with better outcomes. Obvi-
ously, the two trials are not readily com-
parable. In the ORIGIN trial, insulin
glargine treatment was compared with
standard care (14,15), while in the STOP-
NIDDM study acarbose was compared
with placebo (23). Major differences also
exist with respect to study populations
Figure 1dMultivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary
heart disease (CHD), stroke, and all-cause mortality according to fasting and 2-h OGTT plasma
glucose in the DECODE Study. Adapted from ref. 17.
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with high–CV risk diabetic and pre-
diabetic subjects recruited in the ORIGIN
trial versus prediabetic subjects with
no predefined CV risk who participated
in the STOP-NIDDM study. A more di-
rect comparison may be made between
ORIGIN and the Hyperglycemia and Its
Effect After Acute Myocardial Infarction
on Cardiovascular Outcomes in Patients
WithType 2DiabetesMellitus (HEART2D)
(27) study. Patients with longer duration
of diseases (;9 vs. 5.5 years in ORIGIN)
entered the trial within 18 days after an
acute myocardial infarction to be random-
ized to prandial or basal insulin. In spite of
lower fasting plasma glucose concentra-
tion with basal insulin and smoother glu-
cose fluctuations throughout the day with
prandial insulin, no difference in CV event
rates became apparent (HR 0.98 [95% CI
0.8–1.21).
Study population
As already mentioned, high–CV risk sub-
jects were recruited in the ORIGIN trial in
order to assure a sufficient number of CV
events. Besides this common feature, the
study population was, however, hetero-
geneous including 82% of subjects with
known diabetes (average duration 5.4
years) of whom 23% were not taking
any diabetes drug, 6% had newly diag-
nosed type 2 diabetes, and 12% had
IFG/IGT.
To which extent this population may
reflect the overall population of diabetic
and prediabetic individuals is hard to say.
By and large, these subjects had good
glycemic control to start with as indicated
by a median A1C level of 6.4% in both the
insulin glargine and standard care groups.
Nonetheless, ;60% of them had a prior
CV event and 35% had a prior myocardial
infarction. No information is available on
baseline microvascular complications ex-
cept for in 15% of the study population
with some form of albuminuria. Whether
this is a mere CV risk factor (a strong pos-
sibility in this kind of population) or the
sign of diabetic glomerular involvement is
not clear. Nonetheless, the annual rate of
CV events appears to be the highest
among the intervention trials performed
in diabetic patients. As recently pointed
out by Pieber in his commentary on the
ORIGIN trial at the 48th Annual Meeting
of the European Association for the Study
of Diabetes (28), the annual mortality rate
was 2.57% per year, i.e., almost twice that
recorded in other intervention trials (Fig.
2) and greater than the that in the Pro-
spective Pioglitazone Clinical Trial in
Macrovascular Events (PROactive) where
100% of the enrolled patients had some
form of prior CV disease (29). The reason
for this exceedingly high event/mortality
rate is not readily apparent, since age,
BMI, smoking, and prevalence of hyper-
tension were not different among trials.
However, it should be kept in mind that
many of the patients in the ORIGIN trial
were recruited from cardiology practices
with many having their diabetes diag-
nosed after an acute CV event. Therefore,
these patients can be expected to have
higher CV risk than that in the general
diabetes population. Nonetheless, the
generalizability of the results obtained in
the ORIGIN trial to the usual population
of people with diabetes or prediabetes re-
mains highly questionable.
To which extent these unknown risk
features may have affected clinical out-
come also is something to consider. A
main conclusion of the paper is that
insulin glargine had a neutral effect on
CV outcomes. Though they may sound
reassuring, we should agree that these
results do not support the ORIGINal
question as to whether insulin therapy
in subjects with early diabetes and high–
CV risk could reduce CV risk. Moreover,
inspection of the Forest plot presented as
Fig. 2 in the online Supplementary Ap-
pendix of the ORIGIN paper (14) shows
that subjects without prior CV events al-
located to insulin glargine treatment had a
17% increase in the risk of first coprimary
outcome (HR 1.17 [95% CI 1.00–1.37])
compared with an HR of 0.97 (95% CI
0.87–1.07) (P = 0.05 for interaction of
prior CV disease by treatment). For pa-
tients with no prior CV events, these fig-
ures translate to an incidence of 2.21/100
person-years among insulin glargine–
treated subjects compared with 1.89/
100 person-years in subjects on standard
care. Of note, these rates are much higher
than expected for asymptomatic diabetic
patients. In the Detection of Ischemia in
Asymptomatic Patients with diabetes
(DIAD) study, including 1,123 type 2 di-
abetic patients with no symptoms of cor-
onary artery disease, the cumulative
cardiac event rate was 2.9% over a mean
follow-up of 4.8 years for an average of
0.6% per year (30) (Fig. 2).
In summary, the ORIGIN trials have
included a very selected population char-
acterized by high CV morbidity and
mortality in spite of mild hyperglycemia
making extrapolation of the results to
common forms of type 2 diabetes or
prediabetes highly questionable. More-
over, though no difference in CV outcome
was detected in the two treatment arms
when the whole population was consid-
ered, insulin glargine was associated with
increased risk of CV outcome in subjects
with no prior CV disease. This subgroup
analysis casts some doubt about safety of
insulin treatment and prevents drawing of
general conclusions on early insulin ther-
apy and CV risk.
Treatment strategy
In the ORIGIN trial, treatment with in-
sulin glargine was compared with stan-
dard care (mainly oral hypoglycemic
agents). The rationale for using basal
Figure 2dAnnual mortality rate in the ORIGIN, ACCORD, PROactive, and DIAD studies. The
ACCORD trial was prematurely interrupted because of an excess of mortality in the intensively-
treated arm (ref. 7). The PROactive trial included patients with some evidence of prior CV disease
(ref. 28). The DIAD study reported annual mortality in asymptomatic patients (ref. 29).
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insulin replacement has previously been
discussed by the ORIGIN investigators
(15). This was largely based on the con-
cept that inappropriate plasma insulin
concentration relative to tissue insulin re-
sistance results in mobilization of free
fatty acids (FFAs) from adipose tissue
and reduction of HDL (15)dtwo impor-
tant CV risk factors. Unfortunately, in the
study no information is given on insulin
sensitivity, plasma insulin concentration,
or plasma FFA levels, so it is not possible
to ascertain whether any difference oc-
curred with the two treatments on any
of these variables, all of which are inde-
pendent CV risk factors. On the contrary,
serumHDL cholesterol levels are available
showing no changes with insulin glargine
(from 46 6 12 to 45 6 13 mg/dL by the
end of study) or standard care (from 466
12 to 466 13mg/dL), though the 1mg/dL
difference by the end of the study was sta-
tistically different (P, 0.001).
In summary, based on the available
data it is not possible to ascertain whether
the lack of positive effects on CV out-
comes with insulin glargine may be due to
inability, on top of modest improvement
of glycemic control, to assure concomi-
tant amelioration of insulin sensitivity,
plasma FFA, or lipid profile. Alterna-
tively, one could argue that the beneficial
effect generated by the modest glycemic
improvement could be offset by potential
atherogenic impact of chronic hyperinsu-
linemia (Fig. 3) (31). Experimental data
have shown that modest elevation of
plasma insulin levels, mimicking fasting
hyperinsulinemia of insulin-resistant
states, abrogates endothelium-dependent
vasodilation in large conduit arteries,
probably by increasing oxidative stress
(32). Moreover, in the presence of insulin
resistance, hyperinsulinemia, at least in
the in vitro setting, can overstimulate the
intracellular mitogen (mitogen-activated
protein kinase dependent) signaling
pathway in endothelial cells, which, to-
gether with impaired phosphatidylinosi-
tol 3-kinase activation of nitric oxide
synthase, could yield an atherogenic state
(33).
Given the speculative nature of the
above considerations, the fact remains
that insulin glargine treatment in this
high–CV risk population was not associ-
ated with any specific advantage. More-
over, risk-to-benefit ratio of early insulin
intervention must be carefully assessed.
Though rate of hypoglycemia was
claimed to be low, this was three times
higher compared with standard care
(severe hypoglycemia 1.0 vs. 0.3 6/100
person-years, confirmed nonsevere
symptomatic hypoglycemia 9.83 vs.
2.68 6/100 person-years, and nonsevere
symptomatic hypoglycemia 16.72 vs.
5.16/100 person-years; all P , 0.001
[Table 1]), accounting for a larger drop-
out (8.2 vs. 4.1%) among insulin-treated
subjects. The impact of these events is dif-
ficult to extrapolate, but hypoglycemia
has been associated with increased risk
of CV complications (34), impaired qual-
ity of life (35), defensive eating, and body
weight gain (36), as it occurred in the in-
sulin glargine–treated subjects in the
ORIGIN trial (median changes from base-
line 1.6 vs. 20.5 kg). Finally, hypoglyce-
mia remains a major cause of drug-related
hospitalization (37), which, together
with the intrinsic costs of injectable in-
sulin and need for blood glucose moni-
toring, contributes to the excess cost of
diabetes (38).
From this analysis, it may sound
difficult to claim that insulin glargine
treatment may offer much of an advantage
in high–CV risk subjects with mild hyper-
glycemia or dysglycemia compared with
standard care apart from a modest im-
provement in glycemic control. More-
over, insulin treatment seems unlikely to
provide any more durable effect com-
pared with standard care. Analysis of
data presented at the 72nd Scientific Ses-
sions of the American Diabetes Associa-
tion (39) shows that after the initial year
when best glycemic control was attained,
A1C slightly but progressively increased
over the years at a similar rate in the two
intervention arms (insulin glargine 0.061
vs. 0.050% per year [Fig. 4]). What is re-
markable, however, is that with both
treatments excellent and sustained con-
trol was maintained over the 7-year
follow-up with an average A1C level that
remained ,6.5%. Though this may be
sounder when basal insulin therapy is
considered, it is surprising when the effect
of standard care is taken into consider-
ation. The rate of deterioration observed
in the control group, which was mainly
treated with oral agents, is quite different
from the “progressive nature” of type 2
diabetes as described in the UKPDS (6).
In that seminal trial, after the initial 7
years of treatment average A1C was
.7.5% with a progressive and steady in-
crease after initial improvement in glyce-
mic control. The reasons for these
differences between the two trials are
not readily apparent and may include
evolution of the clinical approach and
management over the years as well as dis-
tinctive features of the two study popula-
tions.
Table 1 offers a summary of the
ORIGIN results. It is apparent that insulin
treatment besides a modest improvement
Figure 3dSynopsis of potentially positive and potentially negative effects of insulin with respect
to CV risk (adapted from ref. 30).
care.diabetesjournals.org DIABETES CARE, VOLUME 36, SUPPLEMENT 2, AUGUST 2013 S201
Del Prato and Associates
of glycemic control does not provide any
CV protection at its best while increasing
the risk of hypoglycemia and body weight
gain. Should we than conclude that no
benefit can be expected from early use of
insulin in type 2 diabetes?
Does early insulin treatment
provide any significant benefit?
Two more results were reported from the
ORIGIN trial (14). The first is that there
was no significant difference in cancer
events during the 6-year follow-up (HR
1.0 [95% CI 0.88–1.13]; P = 0.97). This
is good news, which, together with no
adverse effect on CV outcomes, should
provide sufficient confidence to physi-
cians and patients with respect to use of
insulin glargine.
The second “positive” result is the sig-
nificant reduction in the number of
subjects with new diabetes diagnosed 3
months after therapy withdrawal (30 vs.
35% of 1,456 participants without diabe-
tes at baseline; OR 0.80 [95% CI 0.64–
1.00]; P = 0.05). Though this may be
seen as a potential advantage of early use
of insulin in people with prediabetes, its
risk-to-benefit ratio must be fully appre-
ciated. Benefit has to be evaluated with
respect to the potential efficacy, which ap-
pears to be less than the one observed
with lifestyle modification (HR 0.51
[95% CI 0.44–0.60]) (40) or other phar-
macologic agents. In a recent meta-analysis
(41), the use of oral antidiabetes drugs in
prediabetic patients was shown to double
the odds of achieving normoglycemia
compared with control subjects (OR 2.03
[95% CI 1.54–2.67]). When individual
classes of oral antidiabetes drugs were
evaluated, use of thiazolidinediones
(2.33 [1.93–2.81) and a-glucosidase in-
hibitors (2.02 [1.26–3.24]) was associated
with significantly increased odds.With in-
sulin glargine, 15 patients (number
needed to treat) have to be treated for 6
years to prevent 1 new case of type 2 di-
abetes. This figure has to be confronted
with 25 patients treated to incur an event
of severe hypoglycemia (number needed
to harm). This could be judged acceptable
assuming that prevention is persistent and
that only subjects who will develop diabe-
tes will experience severe hypoglycemia. It
would be more questionable if subjects
naturally reverting to normal glucose tol-
erance were exposed to just one of these
severe events.
Conclusions
In summary, the ORIGIN trial could not
document CV benefits from early insulin
treatment in high-risk patients with
recent-onset diabetes while it increases
severe and nonsevere hypoglycemia (Ta-
ble 1). On the other hand, one could read
the trial’s results to conclude that insulin
treatment in high-risk CV patients is not
associated with increased CV or neoplas-
tic event rate. Given prior concern associ-
ated with insulin use, this may be seen as a
reassuring finding.
Insulin glargine also slowed progres-
sion from prediabetes to diabetes, but
cost-effectiveness doubts remain. There-
fore, it is unlikely that ORIGIN strategy
will significantly impact current manage-
ment of diabetes. Moreover, the results of
the ORIGIN trial are not going to put a
final word on the long-debated question
about the best time to initiate insulin
treatment and whether maintenance of
good glycemic control may convey any
CV advantage. Rather, the trial is likely to
ORIGINate more questions.
Though it sounds possible to con-
clude that insulin glargine treatment can
be deemed safe, the choice of an insulin
treatment as initial therapy in type 2
diabetes may not be the most convenient
one unless specific indications exist.
Guidelines (42,43) suggest that insulin
treatment should be considered in all
newly diagnosed type 2 diabetic patients
with elevated A1C levels, particularly if
they are symptomatic. This approach, ir-
respective of unproven CV benefits, still
may provide, per se, some advantages.
When initiated in a symptomatic newly
diagnosed patient, insulin treatment will
result in rapid improvement of glycemic
control and the patient’s well-being.
Whether this approach could provide
Table 1dSummary of the main results of the ORIGIN trial
Insulin glargine
Standard
care P
A1C (%)*
Baseline 6.4 6.4 NS
End of study 6.2 6.5 NS
Primary outcome (100 person-years) 2.94 2.85 NS
Secondary outcome (100 person-years) 5.52 5.28 NS
Hypoglycemia (100 person-years)
Severe 1.0 0.31 ,0.001
Confirmed nonsevere symptomatic 9.83 2.68 ,0.001
Any nonsevere symptomatic 16.72 5.16 ,0.001
Body weight changes from baseline (kg)* 1.6 20.5 d
Cancer (100 person-years)
Any cancer 1.32 1.32 NS
Death from cancer 0.51 0.54 NS
*Median values.
Figure 4dAnnual rate of A1C changes in the insulin glargine–treated subjects and in subjects on
standard treatment after the initial year of treatment (years 1–7).
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some b-cell preservation as suggested in
some studies (44) is a question requiring
further investigation. Nonetheless, insu-
lin treatment can be stopped as soon as
stable improvement is achieved to start
the patient on alternative forms of treat-
ment. The person with diabetes will ap-
preciate that insulin treatment is not
necessarily a forever therapy, and it will
make it easier to restart insulin treatment
when and if that will be needed later in the
natural history of diabetes. In conclusion,
no specific benefits are likely to be ob-
tained with early insulin therapy, once
again suggesting that what matters is to
provide our patients with good glycemic
control before they develop high CV risk
and definitely before they experience a CV
event.
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